New cancer hope for transplant drug

A transplant drug may be given a new role to treat a serious form of cancer, researchers say today.

Rapamycin has been tested as a treatment for pancreatic cancer previously without success.

But a new study says it can be effective against forms of the cancer with a particular genetic fault.

The drug is produced by bacteria and was discovered in soil in Easter Island, also known as Rapa Nui.

The results of the latest laboratory studies have been published in the journal Gut.

Researchers at Glasgow University tested the drug on laboratory mice and found that cancers with a fault in the PTEN gene seemed to react to it – stopping spreading.

About one in five cases of pancreatic cancer involve this gene, the researchers say.

Researcher Dr Jennifer Morton said: “This is incredibly important research showing for the first time that there’s potential to tailor treatment to pancreatic cancer patients based on differences in their tumour’s genetic fingerprint.

“Although it’s at a very early stage, it’s the first time we’ve been able to pinpoint a genetic fault in pancreatic cancers and match it up with a specific drug."

Dr Kat Arney, of Cancer Research UK, which backed the research, said: “This is a promising step towards being able to understand how pancreatic tumours differ from each other and how we can personalise treatments to them."

Morran DC et al. Targeting mTOR dependency in pancreatic cancer (2014) Gut. doi: 10.1136/gutjnl-2013-306202. Gut 4 August 2014 [abstract]

,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index